- Home
- MRM vs ICU Comparison
MRM vs ICU Comparison
Compare MRM & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRM | ICU |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 9.1M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRM | ICU |
|---|---|---|
| Price | $1.05 | $4.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.5K | ★ 84.3K |
| Earning Date | 05-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $53.00 |
| Revenue Next Year | N/A | $50.00 |
| P/E Ratio | $32.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $0.22 |
| 52 Week High | $4.45 | $5.10 |
Technical Indicators
Market Signals| Indicator | MRM | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 35.63 | 58.54 |
| Support Level | N/A | $2.26 |
| Resistance Level | $1.26 | $4.89 |
| Average True Range (ATR) | 0.07 | 0.36 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 0.00 | 61.00 |
Price Performance
Historical ComparisonAbout MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.